• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23378 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ezetimibe for hypercholesterolaemia]
2008     Committee for New Health Technology Assessment (CNHTA) [Eyeball brachytherapy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating devices]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating device]
2009     Committee for New Health Technology Assessment (CNHTA) [Extremely low temperature cool chamber]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracranial stereotactic body radiotherapy in oligometastasis]
2004     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal shock-wave treatment in orthopedics and rehabilitation. Update]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal shock wave therapy in musculoskeletal disorders]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Extracorporeal shock wave therapy for orthopaedic indications]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Extracorporeal shock wave therapy (ESWT) for the treatment of delayed union or non-union of fractures]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extracorporeal shock wave therapy (ESWT) for heel pain]
2009     Committee for New Health Technology Assessment (CNHTA) [Extracorporeal photopheresis]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Extracorporeal photopheresis: main indications and implementation parameters]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal liver support of liver failure by means of Prometheus system]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Extracorporeal High-Intensity Focused Ultrasound (HIFU) in solid tumours]
2008     Basque Office for Health Technology Assessment (OSTEBA) [External review and validation of methodological instruments for the critical reading and summary of scientific evidence]
2007     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [External manual. Part 1]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [External evaluation of DACEHTA]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [External evaluation of cancer care organization and delivery: review of experiences relevant to the cancer team evaluation and designation process in Québec]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2012     Andalusian Health Technology Assessment Area (AETSA) [Extended neonatal screening for lysosomal diseases by mass spectrometry]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extended adjuvant endocrine therapy in breast cancer]
2006     Andalusian Health Technology Assessment Area (AETSA) [Expulsion stage of delivery: comparison of upright versus lying down positions for childbirth, through maternal and foetal outcomes]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploratory examination of the need for revision of the DMP "coronary heart disease"]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Exploratory evaluation of the relevance, use, and impacts of teleconsultations]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Surgery for varices" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Decompression for carpal tunnel syndrome" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Conization of the cervix uteri" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Cataract surgery" -Rapid report]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Expertise on endometriosis]
2020     National Committee for Technology Incorporation (CONITEC) [Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Expanding thrombolysis in acute ischemic stroke: organizing effective and efficient daily care in The Netherlands]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy in patients with peripheral arterial disease: the costs and effectiveness of physiotherapeutic supervision with or without therapy feedback versus a 'go home and walk' advice]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy for patellofemoral pain syndrome: a randomised clinical trial in general practice and sports medicine]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Exercise therapy (Krankengymnastik / Heilgymnastik) in physical medicine]
2020     HTA South [Exercise test in the investigation of suspected chronic coronary syndrome: a comparison with imaging and other functional tests]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exenatide in diabetes mellitus type 2 - Rapid report]
2020     National Committee for Technology Incorporation (CONITEC) [Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Exantia® tissue bulking agent for the treatment of fecal incontinence]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target population]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Examination of barriers and facilitators for the implementation of clinical practice guidelines: a Delphi study]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Examination and treatment of older people after a fall – a health technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for vascular access care]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for fall prevention]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence-based patient information on chronic obstructive airway diseases - Asthma]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: xanthine oxidase inhibitors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: treatment of comorbidities]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: test accuracy of various methods for diagnosing gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: lifestyle changes for gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: drug treatment of a gout attack]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: allopurinol versus febuxostat]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Technical support systems]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structured information on the initial diagnosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structural imaging]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Dementia care management]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Cognitive training / cognitive stimulation]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: timing of nutrition in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional interventions in chronic pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Evidence overview of therapeutic hypothermia]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence on orphan drugs]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Evidence brief on the measures related to the reimbursement of blood glucose test strips]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Everolimus (Afinitor) for the treatment of renal cell carcinoma]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of vascular care in Alzheimer's disease]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the utility and indication of prostate biopsies with image fusion – magnetic resonance and transrectal ultrasound]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]
1998     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of the use of antidigoxin antibodies in the treatment of digitalis intoxication]
2018     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the ultrasonic flowmeter for verification of graft patency during coronary artery bypass grafting]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Evaluation of the service offer from the Centre d'expertise pour les victimes de brûlures graves de l'est du Québec (CEVBGEQ) in relation to the use of pressure garments to treat scarring in severe burn patients]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the scientific evidence on nipple-areola complex micropigmentation, requirements for its proper implementation and costs]